Aggarwal, Ishita

Barreca, Antonella

Cuadrado, Maria J.

Dall&apos

Fenoglio, Roberta

Papotti, Mauro

Radin, Massimo

Roccatello, Dario

Schreiber, Karen

Sciascia, Savino

Yazdany, Jinoos

English

Institutional Research Information System University of Turin

iris-AperTO University of Turin’s Institutional Research Information System and Open Access Institutional Repository      This is the author's final version of the contribution published as:  Sciascia S, Yazdany J, Dall’Era M, Fenoglio R, Radin M, Aggarwal I, Cuadrado MJ, Schreiber K, Barreca A, Papotti M, and Roccatello D. Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: a multicenter cohort study.  Ann Rheum Dis. 2018 Dec 14. pii: annrheumdis-2018-214559. doi: 10.1136/annrheumdis-2018-214559.   The publisher's version is available at: https://ard.bmj.com/content/early/2018/12/14/annrheumdis-2018-214559.long  When citing, please refer to the published version.   Link to this full text:  http://hdl.handle.net/2318/1688837              This full text was downloaded from iris-Aperto: https://iris.unito.it/   1 Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: a multicenter cohort study   Sciascia S1,2, Yazdany J3, Dall’Era M3, Fenoglio R2, Radin M1, Aggarwal I3, Cuadrado MJ4,5, Schreiber K5,6,7, Barreca A8, Papotti M8, and Roccatello D1,2.  1.Center of Research of Immunopathology and Rare Diseases- Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy  2. SCU Nephrology and Dialysis(ERKnet member), S. Giovanni Bosco Hospital, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy 3.Division of Rheumatology, Russell/Engleman Research Center, University of California, San Francisco, San Francisco, California 4. Lupus Unit, Department of Rheumatology, Guy's and St Thomas' Hospital, London, United Kingdom 5.Department of Thrombosis and Haemophilia, Guy's and St Thomas' Hospital, London, United Kingdom. 6. King Christian X’s Rheumatology Hospital, Graasten, Denmark.  7. Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases,Copenhagen, Denmark. 8.Division of Pathology, Department of Medical Sciences, University of Turin, Turin, Italy.  Running headline: anticoagulation in LN and TMA  2  Corresponding Author:  Savino Sciascia, MD PhD Center of Research of Immunopathology and Rare Diseases- CMID, Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, and Nephrology and Dialysis Division (ERKnet member), Department of Clinical and Biological Sciences of the University of Turin, and San Giovanni Bosco Hospital, Turin, Italy savino.sciascia@unito.it Tel 00390112402051Fax 00390112402052  The authors declare no conflict of interest and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.   3 The management of lupus nephritis (LN) and concomitant thrombotic microangiopathy (TMA), with or without antiphospholipid antibodies (aPL), remains controversial and few studies are available to inform clinical management [1–4] The purpose of this multicenter retrospective study was to analyze the impact of anticoagulation [vitamin-K-antagonists (VKA)  and/or heparins] in addition to conventional immunosuppression on kidney outcomes (assessed at 12 months, according to KDIGO guidelines[5]) in patients with biopsy-proven LN and concomitant TMA.  Data source, population, and statistical analysis are detailed in the supplementary material. Anticoagulation was considered if given for at least 3 consecutive months after TMA diagnosis.  We retrospectively identified 97 patients with biopsy-proven LN and TMA (2007-2017). See online supplementary Table S1 for clinical and demographic characteristics. Laboratory parameters were collected at the time of the biopsy. The mean age of patients was 38.9 ±15.2 years (13–69) and 85 female (87.6%). Most had proliferative LN (Class IV in 84.5%). Forty-two(43%) patients presented with acute and 55 (57%) with features of chronic TMA. All patients had received treatment with standard immunosuppressants (55% mycophenolate, 39% cyclophosphamide, 6% other regimen) and steroids. At 12 months, complete response (CR) was observed in 37 patients (38.1%), partial response (PR) in 22 (22.6%) and no response in 38 (39.1%). Sixty-one patients (62.9%) were aPL positive and 37 (38.1%) of these patients received anticoagulation with a VKA and/or heparins. Mean duration of anticoagulation therapy after TMA and LN diagnosis was 7.7 months (3-12).   4 We observed a higher rate of clinical response (CR/PR, together or computed separately) in patients who received anticoagulation [CR in 22 (59.46%), PR in 7 (18.91%); NR in 8 (21.62%)] when compared to those without [CR in 15 (25.0%), PR in 15 (25.0%); NR in 30( 50%)], p<0.01) (Table1). When limiting the analysis on the 61 patients with aPL, we observed a higher rate of complete response in those receiving anticoagulation [patients receiving anticoagulant therapy: CR in 22 (59.46%), PR in 7 (18.91%); NR in 8 (21.62%) Vs. patients non receiving VKA/heparins: CR in 8 (30.77%), PR in 7 (26.92%); NR in 8 (34.62%),p=0.046](Figure 1). After multivariate analysis, aPL positivity (any) (β=1.23,OR, 2.4;95% confidence interval-CI-, 1.2–7.3;p=0.03), anti-dsDNA positivity (β=1.98,OR,12.8; 95% CI 3.0-71.3; p=0.002), and chronic features of TMA (β=1.31,OR 3.0; 95%CI 1.2–17.5; p =0.04) were all associated with no kidney response. When limiting the analysis to aPL positive patients, after adjusting for type of immunosuppressant therapy and LN class, variables that were significantly associated with CR+PR were features of acute TMA rather than chronic (β=1.95, OR, 8.62; 95% CI 1.4–97.1; p = 0.03) and the use of VKA/heparins (β=1.21OR, 2.1; 95% CI, 1.02–16.2; P = 0.046).   In summary, in our study the use of anticoagulation was associated with any response to treatment at 1 year, in line with the fact that about 60% of the patients with CR received VKA or heparins. Similarly, when limiting the analysis to patients with aPL, we observed a rate of any response (either CR+PR) as high as 66% in patients receiving anti-coagulant treatment when compared to those receiving immunosuppression alone (34%).   5 Despite its limitations (the relatively short duration of follow-up to gauge the relapse rate; lack of standardized protocol for LN treatment; the use of anticoagulation agents was not randomized but based on the treating physicians’ judgment), this study represents the largest available multicentre cohort of real-life SLE patients with biopsy proven LN and concomitant TMA.  To conclude, in patients with concomitant LN and TMA, the use of anticoagulation appeared protective and warrants further investigation as a therapeutic tool; the presence of aPL, anti-dsDNA antibodies and chronic features of TMA were associated with poorer kidney outcomes.      6 1  Mejía-Vilet JM, Córdova-Sánchez BM, Uribe-Uribe NO, et al.Prognostic significance of renal vascular pathology in lupus nephritis. Lupus 2017;26:1042–50. doi:10.1177/0961203317692419 2  Pattanashetti N, Anakutti H, Ramachandran R, et al.Effect of Thrombotic Microangiopathy on Clinical Outcomes in Indian Patients With Lupus Nephritis. Kidney Int reports 2017;2:844–9. doi:10.1016/j.ekir.2017.04.008 3  Sciascia S, Cuadrado MJ, Khamashta M, et al. Renal involvement in antiphospholipid syndrome. Nat Rev Nephrol 2014;10:279–89. doi:10.1038/nrneph.2014.38 4  Moroni G, Ventura D, Riva P, et al.Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. Am J Kidney Dis 2004;43:28–36.http://www.ncbi.nlm.nih.gov/pubmed/14712424 (accessed 2 Apr 2018). 5  KDIGO Clinical Practice Guideline for Glomerulonephritis KDIGO Clinical Practice Guideline for Glomerulonephritis KDIGO Clinical Practice Guideline for Glomerulonephritis. Published Online First: 2012.http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-GN-Guideline.pdf (accessed 4 Jun 2018).    7 Acknowledgment  Manuscripts based on work previously presented at the following conferences and published as a conference abstract.  ACR 2018: https://acrabstracts.org/abstract/clinical-outcomes-and-response-to-anti-thrombotic-treatment-among-patients-with-concomitant-lupus-nephritis-and-thrombotic-microangiopathy-a-multicenter-cohort-study/?msg=fail&shared=email EULAR 2018: https://web.eular.org/EULAR_Production/2018_Amsterdam.nsf/fmWebPGMbyDayPublic?OpenForm    Legends:   Figure 1  Comparison of kidney outcomes between patients receiving anticoagulation and those without (Panel A, all 97 patients; Panel B, limiting to patients positive for antiphospholipid antibodies) Table 1. Univariate analysis of patient characteristicsby kidney outcome  Table 1S. Baseline clinical characteristics of patients with TMA and LN      8 Table 1S Characteristics  Total % Female  85 87,6 Clinical features  Skin Involvement  32 33,0 Hematological involvement  35 36,1 Joint involvement  75 77,3 NPSLE  2 2,1 History of hypertension   55 56,7 APS*  13 13,4 Thrombotic APS  10 10,3 Obstetric APS  5 5,2 Clinical features at the time of biopsy Microangiopathic hemolytic anemia   3 3,1 Thrombocytopenia (<100,000 platelets/μL)   15 15,5 Laboratory profile  Anti-Ro positivity   36 37,1 Anti-La positivity   9 9,3 aPL antibody positivity  61 62,9 LAC  37 38,1 aCL  35 36,1 anti-Beta2GPI  22 22,7 Triple Positivity  15 15,5 Anti-dsDNA  43 44,3 Creatinine > 3 mg/dL  27 27,8 low C3 levels   77 79,3 low C4 levels   27 27,8 Microscopic hematuria (>5 erythrocytes/HPF)  69 71,1 Proteinuria > 3.5 mg/d  41 42,3 Arterial hypertension  63 64,9 Hyperlipemia  45 46,3 aGAPPS ≥ 10  29 29,9 aGAPPS ≥ 12  24 24,7 Therapy ACE inhibitor or ARB use  62 63,9 Anti-thrombotic therapy    Aspirin**  54 55,7 Anticoagulation***  38 39,2 Vitamin K antagonist  31 32,0 heparins  7 7,2 Immunosuppressants (Induction therapy for LN)****    Mycophenolate mofetil  53 54,6 Cyclophosphamide   38 39,2 EUROLUPUS regimen  28 28,9  9    *according to Sydney criteria (Miyakis et al., 2006); **in 47 patients treatment was initiated before LN diagnosis;  *** 10 patients on VKA before LN diagnosis; **** patients received different steroids regimens in association to immunosuppressant agents. The majority of them receive bolus doses of methyl-prednisone followed by 0.8/kg/day of oral prednisone tapered to low-dose (e.g. < 7.5 mg/dl) within 6 months from induction. NPSLE, neuropsychiatric SLE; Miyakis, S., Lockshin, M. D., Atsumi, T., Branch, D. W., Brey, R. L., Cervera, R., … Krilis, S. A. (2006). International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of Thrombosis and Haemostasis : JTH, 4(2), 295–306. Other  6 6,2  10 Table 1  Characteristics   Total % Any response % CR % %CR PR % %PR NR % %NR p p* Female 85 87,6 52 53,6 30 30,9 81,1 22 22,68041 100 33 34,02 86,84 0,2924 0,85 Clinical features                            APS* 13 13,4 10 10,3 5 5,2 13,5 5 5,2 22,7 3 3,1 7,9 0,2629 0,22 aPL antibody positivity 61 62,9 26 26,8 15 15,5 40,5 11 11,3 50,0 35 36,1 92,1 <0.001 <0.001 LAC 37 38,1 17 17,5 7 7,2 18,9 10 10,3 45,5 20 20,6 52,6 0,0079 0,018 aCL 35 36,1 20 20,6 8 8,2 21,6 12 12,4 54,5 15 15,5 39,5 0,0334 0,57 anti-Beta2GPI 22 22,7 12 12,4 7 7,2 18,9 5 5,2 22,7 10 10,3 26,3 0,7464 0,49 Triple Positivity 15 15,5 8 8,2 5 5,2 13,5 3 3,1 13,6 7 7,2 18,4 0,811 0,51 Anti-dsDNA 43 44,3 22 22,7 13 13,4 35,1 9 9,3 40,9 24 24,7 63,2 0,041 0,0214 Low C3 levels  77 79,3 36 37,1 25 25,8 67,6 11 11,3 50,0 38 39,2 100,0 0,001 <0.001 Low C4 levels  27 27,8 15 15,5 8 8,2 21,6 7 7,2 31,8 12 12,4 31,6 0,5627 0,64 Arterial hypertension   63 64,9 36 37,1 23 23,7 62,2 13 13,4 59,1 28 28,9 73,7 0,4252 0,27 Hyperlipemia   45 46,3 27 27,8 17 17,5 45,9 10 10,3 45,5 18 18,6 47,4 0,98 1 aGAPPS ≥ 12   24 24,7 10 10,3 6 6,2 16,2 4 4,1 18,2 14 14,4 36,8 0,0846 0,0267 LN class IV 82 84,5 50 51,5 32 33,0 86,5 18 18,6 81,8 32 33,0 84,2 0,8891 1 Therapy                               Mycophenolate mofetil 53 54,6 32 33,0 21 21,6 56,8 11 11,3 50,0 21 21,6 55,3 0,8764 1 Cyclophosphamide  38 39,2 22 22,7 14 14,4 37,8 8 8,2 36,4 16 16,5 42,1 0,888 0,67 EUROLUPUS regimen 28 28,9 16 16,5 11 11,3 29,7 5 5,2 22,7 12 12,4 31,6 0,7583 0,65 Other immunosuppresants 6 6,2 4 4,1 2 2,1 5,4 2 2,1 9,1 2 2,1 5,3 0,8128 1 Anticoagulation 37 38,1 29 29,9 22 22,7 59,5 7 7,2 31,8 8 8,2 21,1 0,0022 0,0059  11 *computing together any response, CR+PR. CR, complete response; PR, partial response; NR, no response; aGAPPS, adjusted global antiphospholipid score.   12  

Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: A multicentre cohort study

https://iris.unito.it/retrieve/handle/2318/1688837/470267/2318_1688837.pdf

Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: A multicentre cohort study

Abstract

Similar works

Full text

Available Versions

Institutional Research Information System University of Turin